stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Net income
Tango Therapeutics, Inc.'s net income for fiscal 2025 was −$101.6M, compared with −$130.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$123.7M. Over the past ten years it has ranged from −$130.3M (fiscal 2024) to $0.00 (fiscal 2019); the current reading is higher than 50% of that period. Tango Therapeutics, Inc. ranks 452nd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$101.6M | — |
| FY2024 | −$130.3M | — |
| FY2023 | −$101.7M | — |
| FY2022 | −$108.2M | — |
| FY2021 | −$58.2M | — |
| FY2020 | −$52.0M | — |
| FY2019 | $0.00 | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$55.3M | — |
| Mar 2026 | −$45.5M | — |
| Dec 2025 | −$38.7M | — |
| Sep 2025 | $15.9M | — |
| 21 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| TNGX Tango Therapeutics, Inc. | −$123.7M |
| ABCL AbCellera Biologics Inc. compare | −$164.7M |
| PBLS Parabilis Medicines, Inc. compare | −$170.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$197.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$220.5M |
| IRON Disc Medicine, Inc. compare | −$245.9M |
| RLAY Relay Therapeutics, Inc. compare | −$286.0M |
| XENE Xenon Pharmaceuticals Inc. compare | −$409.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TNGX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement